Zydus Lifesciences (ZYDUSLIFE) Share Price Falls 2.03% Today

Zydus Lifesciences Share Price fell to Rs 1,126.7 on 09 September 2026, down 2.03% for the day. The move took the Large Cap pharmaceutical company’s market capitalisation to Rs 1,15,211.69 crore. Intraday, the stock opened at Rs 1,145.05, touched a high of Rs 1,157.65, and slipped to a low of Rs 1,126.25, leaving it near the session low when this update was prepared.

The verified market data shows a decline of Rs 23.3 from the previous close of Rs 1,150, with turnover of Rs 16.2 crore. The stock is in focus because a large healthcare name saw a meaningful one-day decline. However, the supplied data does not establish any company-specific catalyst for today’s move. What it does show is that the business continues to trade with a P/E ratio of 25.42, P/B ratio of 4.25, ROE of 19.69%, and ROCE of 21.39%. That makes the price move worth reading alongside the company’s broader valuation and profitability profile.

Zydus Lifesciences (ZYDUSLIFE) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,126.7
Previous Close	Rs 1,150
Today's Move	-Rs 23.30 (-2.03%)
Open	Rs 1,145.05
High	Rs 1,157.65
Low	Rs 1,126.25
Turnover	Rs 16.2 crore
Market Capitalisation	Rs 1,15,211.69 crore
Market Cap Category	Large Cap

Zydus Lifesciences Share Price Today reflects a weak session rather than a brief dip. The stock began below the previous close, briefly moved higher, and then lost ground through the day. The fact that the current price remained only marginally above the low suggests sellers retained control into the later part of the session.

The intraday path is straightforward. After opening at Rs 1,145.05, the stock rose to Rs 1,157.65, showing that there was some early support. That did not hold. The price then declined to Rs 1,126.25, and the last tracked price of Rs 1,126.7 kept it very close to the session bottom. For market participants, that kind of closing position often attracts more attention than a lower close alone because it indicates sustained weakness across the trading day.

Turnover of Rs 16.2 crore also points to active trading interest in a Large Cap counter. The supplied data does not confirm whether the pressure came from company news, broader sector sentiment, or purely market positioning, so it is best to avoid assigning a cause that is not evidenced here.

Zydus Lifesciences (ZYDUSLIFE) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,15,211.69 crore
P/E Ratio	25.42x
P/B Ratio	4.25x
ROE	19.69%
ROCE	21.39%
EPS	Rs 45.24
Book Value Per Share	Rs 270.31
Dividend Yield	0.09%

Zydus Lifesciences Fundamental Analysis still points to a large and profitable pharma business despite today’s decline. The stock trades at 25.42 times earnings and 4.25 times book value, while EPS stands at Rs 45.24 and book value per share at Rs 270.31. Dividend yield is 0.09%.

The profitability metrics are notable. ROE of 19.69% indicates strong returns on shareholder equity, and ROCE of 21.39% shows healthy returns on overall capital employed. Those figures matter because price weakness in the short term does not automatically alter the company’s reported return profile. In that sense, today’s move is best read as a market-price event occurring against a still solid profitability backdrop.

For investors reviewing the stock, the mix is clear: a Large Cap company, moderate earnings valuation by industry standards, and return ratios that remain comfortably positive. That combination is one reason the decline may draw attention even without a confirmed trigger in the provided data.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	25.42x
Benchmark Median P/E	32.19x
Benchmark Average P/E	49.13x
Benchmark P/E Range	3.39x to 668.68x
Company P/B Ratio	4.25x
Benchmark Median P/B	3.05x
Benchmark Average P/B	4.44x
Company ROE	19.69%
Benchmark Median ROE	11.82%
Benchmark Average ROE	11.12%
Company ROCE	21.39%
Benchmark Median ROCE	13.71%
Benchmark Average ROCE	13.62%
Company Market Capitalisation	Rs 1,15,211.69 crore
Benchmark Median Market Cap	Rs 715.6 crore
Benchmark Average Market Cap	Rs 14,150.82 crore

Zydus Lifesciences operates in Healthcare, within Pharmaceuticals & Drugs. The same-industry benchmark covers 201 companies, which gives a useful frame for reading both valuation and profitability.

On earnings valuation, the company’s P/E of 25.42 is below the industry median of 32.19 and well below the average of 49.13. Since the industry P/E range runs from 3.39 to 668.68 across 169 companies with available data, Zydus does not look extreme on this measure.

On book value, the P/B ratio of 4.25 is above the industry median of 3.05 but slightly below the average of 4.44. Profitability is where the company compares more strongly. ROE of 19.69% is above both the median of 11.82% and the average of 11.12%, while ROCE of 21.39% is above the median of 13.71% and average of 13.62%. Its market capitalisation of Rs 1,15,211.69 crore is also far above the industry median of Rs 715.6 crore and higher than the industry average of Rs 14,150.82 crore.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,55,825.66	37.31	5.22	14.85	19.11
Divi's Laboratories	DIVISLAB	2,47,018.51	86.86	14.38	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,86,874.73	86.55	21.03	26.76	19.27
Cipla	CIPLA	1,12,773	33.17	3.18	11.83	16
Laurus Labs	LAURUSLABS	1,00,943.83	96.14	18.64	18.31	18.2

Peer data places Zydus among the larger listed pharma names, with valuation that looks lower than several well-followed peers. Against Sun Pharmaceutical Industries, Zydus trades at a lower P/E of 25.42 versus 37.31, while showing higher ROE and ROCE than Sun Pharma’s 14.85% and 19.11%.

Compared with Divi’s Laboratories and Torrent Pharmaceuticals, the valuation gap is much wider. Both trade above 86 times earnings, while Zydus remains at 25.42 times. Divi’s ROCE of 21.51% is only slightly above Zydus, while Torrent’s ROE of 26.76% is stronger but its ROCE of 19.27% is lower.

Against Cipla, the market capitalisations are close at Rs 1,15,211.69 crore for Zydus and Rs 1,12,773 crore for Cipla. Zydus also has a lower P/E than Cipla’s 33.17 and stronger ROE and ROCE than Cipla’s 11.83% and 16%. Laurus Labs trades at a far higher P/E of 96.14 and P/B of 18.64 despite a smaller market capitalisation of Rs 1,00,943.83 crore. On the supplied peer set, Zydus screens as comparatively moderate on earnings valuation.

Why Investors Are Watching Zydus Lifesciences

• The stock fell 2.03% to Rs 1,126.7 and stayed close to the day’s low of Rs 1,126.25.
• It moved from Rs 1,145.05 at the open to Rs 1,157.65 at the high before weakening through the session.
• The P/E ratio of 25.42 is below the industry median of 32.19.
• ROE of 19.69% and ROCE of 21.39% are above the industry median and average.
• With a market cap of Rs 1,15,211.69 crore, it remains a major Healthcare stock within the listed pharma space.

About Zydus Lifesciences

Zydus Lifesciences is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. By market capitalisation, it is much larger than the industry median and also above the industry average, which helps explain why a one-day move in the stock can attract broad investor attention.

Its peer set in the supplied data includes Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Cipla, and Laurus Labs. Relative to that group, the company combines scale with above-benchmark profitability and a lower earnings multiple than several prominent peers.

Track Zydus Lifesciences Share Price on Univest

UseZydus Lifesciences (ZYDUSLIFE) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

Zydus Lifesciences Share Price can be tracked on Univest alongside valuation ratios, peer comparison, shareholding pattern, 52-week levels, and broader market context, helping readers assess whether a single-day decline changes the bigger picture.

Frequently Asked Questions

Why is Zydus Lifesciences Share Price falling today?

Ans. Zydus Lifesciences Share Price fell 2.03% to Rs 1,126.7 from the previous close of Rs 1,150. The supplied market data confirms the decline, but it does not establish a company-specific catalyst.

What is Zydus Lifesciences Share Price Today?

Ans. The stock is at Rs 1,126.7, down Rs 23.3 or 2.03% in the session. The previous close was Rs 1,150. The intraday range extended from Rs 1,126.25 to Rs 1,157.65.

What do valuation and profitability metrics show?

Ans. The stock trades at a P/E of 25.42 and P/B of 4.25, while ROE is 19.69% and ROCE is 21.39%. The relevant peer median P/E is 32.19x. The peer average P/E is 49.13x.

How does it compare with industry benchmarks?

Ans. Its P/E is below the industry median of 32.19, while both ROE and ROCE are above the corresponding industry medians. The stock belongs to the Healthcare sector. Its industry classification is Pharmaceuticals & Drugs.